The role of Fas-mediated apoptosis in thyroid disease

M Andrikoula and A Tsatsoulis

Division of Endocrinology, Department of Medicine, University of Ioannina Medical School, Ioannina 45110, Greece

(Correspondence should be addressed to A Tsatsoulis; Email: atsatsou@cc.uoi.gr)

Abstract

Recent evidence has emphasized the importance of apoptosis in the maintenance of tissue homeostasis and the pathogenesis of malignant and immune diseases. Autoimmune thyroid diseases such as Hashimoto’s thyroiditis and Graves’ disease, as well as other autoimmune endocrine diseases, have been associated with dysregulation of apoptotic signaling pathways. In particular, dysfunction of the Fas apoptotic pathway or production of soluble factors including soluble Fas and soluble Fas ligand may be involved in the pathogenesis of these disorders. On the other hand, malignant thyroid cells may avoid Fas-mediated suicide possibly by expression of inhibitors of apoptosis and evade the immune system by inducing apoptosis on infiltrating lymphocytes. The delicate balance between cell proliferation and cell death through the Fas pathway may also play an important role in the control of thyroid cell mass and goitrogenesis. This review analyzes the current evidence on the role of Fas-mediated apoptosis in the pathogenesis of thyroid diseases including Hashimoto’s thyroiditis, Graves’ disease, thyroid cancer and goiter. However, the exact mechanisms involved in the regulation of apoptosis in thyroid disease remain unclear. Further investigation is needed.

European Journal of Endocrinology 144 561–568

Introduction

The term ‘apoptosis’ was introduced into modern scientific writing by Kerr et al. in 1972 (1) to describe the special morphology of physiological cell death. The word itself is an ancient Greek word meaning the ‘falling off’ of leaves from a tree or petals from a flower and was originally used in the medical and philosophical writings of classical Greek and Roman times (2).

Apoptosis or ‘programmed cell death’ represents the regulated activation of a pre-existing death program encoded in the genome. It is a highly orchestrated form of cell death and plays a central role in the control of tissue cell numbers during development and homeostasis together with important functions, such as cell proliferation and differentiation (3–5). Dysregulation of apoptosis, on the other hand, may be involved in the pathogenesis of human disease (6). To date, diseases of the endocrine system such as Hashimoto’s thyroiditis (HT), Graves’ disease (GD) and diabetes mellitus type 1 have been considered to be autoimmune in origin. Recent evidence suggests that programmed cell death is also involved in the pathogenesis of these disorders. The Fas pathway has been demonstrated to be an important apoptotic pathway in the thyroid, but its role in the pathogenesis of thyroid diseases is controversial and a subject of much debate. This review summarizes the available evidence on the role of Fas-mediated apoptosis in thyroid diseases such as autoimmune thyroiditis, GD, thyroid cancer and goiter. An understanding of the function and regulation of the Fas pathway in the thyroid may provide insights into potential pathogenic mechanisms and may enable the design of more effective strategies for prevention and treatment of thyroid diseases.

Apoptosis induction by Fas

There are two major pathways leading to apoptosis: (a) positive induction by ligand binding to a plasma membrane receptor and (b) negative induction by loss of a trophic signal. The apoptotic mechanism of a cell involves the death receptors, the adaptor molecules, the caspase cascade, the mitochondria and the Bcl-2 proteins (7, 8).

The death receptors known today belong to the tumor necrosis factor receptor (TNFR) gene superfamily which is defined by similar, cystein-rich extra cellular domains. The death receptors form a subgroup of the superfamily TNFR, containing a homologous cytoplasmic sequence of 80 amino acids termed the ‘death domain’ (9, 10). The death domain (DD) bridges the death receptors with the apoptotic machinery, but in some cases they mediate functions different from apoptosis, such as the activation of the nuclear factor κB (NK-κB). Some adaptor molecules transmitting...
apoptotic signals from death receptors contain DDs themselves.

One of the best characterized death receptors is CD95/Fas (Fig. 1). As soon as it is activated by its ligand, Fas ligand/CD95L, the apoptotic signal is transmitted through the adaptor molecule Fas-associated DD (FADD)/Mort1 to the zymogen form of cysteiny1-aspartate-specific protease (caspase)-8 termed FLICE (FADD-like interleukin-1β converting enzyme) (11). Upon recruitment by FADD, caspase-8 oligomerization leads to its activation through self-cleavage (12). Subsequently, caspase-8 activates downstream effector caspases, such as caspase-9, causing an apoptotic demise of the cell. Studies with mice lacking the FADD gene indicated that this adaptor molecule is essential for apoptosis induction by Fas (13). The activation of caspases plays a pivotal role in the initiation and execution of apoptosis induced by various stimuli. To date, 14 different members of caspases have been identified in mammalian cells.

The gene responsible for Fas protein is located on human chromosome 10. The Fas antigen is a 335 amino acid, type I cell surface protein belonging to the TNFR family (14, 15). FasL is a type II transmembrane protein of the same family, which has the ability to bind to Fas (16). The induction of the apoptotic mechanism requires Fas activation either by anti-Fas antibody or by FasL. Like other TNF family members, FasL is a homotrimeric molecule, which means that each FasL trimer binds three Fas molecules (10).

It is already known that Fas and FasL play an important role in three types of physiologic apoptosis: (1) peripheral deletion of activated mature T cells at the end of an immune response, (2) killing of targets such as various infected cells or cancer cells by cytotoxic T cells and by natural killer cells (Fig. 2), and (3) killing of inflammatory cells at ‘immune-privileged’ sites such as the eye and the testis (16, 17).

Recent studies indicate that apoptosis induced by Fas–FasL is implicated in the pathogenesis of autoimmune endocrine diseases, such as GD, HT, diabetes mellitus type 1 and Addison’s disease.

The role of the Fas pathway in immune-mediated apoptosis

The central pathogenic event in the development of autoimmune endocrine diseases is the immune-mediated destruction of endocrine cells. HT is caused by the cytotoxicity of thyroid follicular cells (18). A similar mechanism is considered to lead to Addison’s disease, where cytotoxicity of adrenal cortical cells results in adrenal insufficiency (19), and type 1 diabetes mellitus where cytotoxicity of islet β cells results in inadequate insulin secretion and hyperglycemia (20). Islet β cells were found to be destroyed by apoptosis in both animal models of diabetes and in humans with type 1 diabetes. However, when β cell cytotoxicity mediated by Fas was prevented, the animals did not develop diabetes (21). Thus, apoptosis induced by Fas is probably involved in the pathogenesis of autoimmune diseases of the endocrine glands, including the thyroid.

Immunohistochemical studies of thyroid tissue sections revealed an increased number of apoptotic follicular cells in HT (22–24), most of them on the periphery of infiltrating lymphocytes. Conversely, the number of apoptotic cells is decreased in GD where the lymphocytic infiltration is milder. The above findings suggest that the apoptotic destruction of thyroid tissue is mediated by the immune system with mechanisms that remain unclear.
According to recent evidence, CD8 cells cause cellular cytotoxicity in target cells not by necrosis or inflammatory destruction of the cells, but through the induction of apoptosis (25). Apoptosis is induced by triggering of membrane receptors of the target cells either by ligands on the lymphocytes or soluble factors that are released and delivered to the target cell (26).

Fas ligand expression is increased on activated natural killer cells, resulting in an increased cytotoxicity potential of these cells. Tumor cells often escape immune surveillance by down-regulation of Fas antigen or by constitutive expression of FasL (27).

Therefore, the Fas pathway plays a central role in immune-mediated apoptosis and the regulation of immune responses. This is the reason why recent studies of the pathogenesis of autoimmune thyroid disease have focused on this death pathway and its regulatory function in the thyroid gland.

Figure 2 T cell interactions with tumor cells. (A) The T cell recognizes tumor cells via the T cell receptor (TCR) and kills them by Fas–FasL interaction or by releasing perforin/granzyme. (B) Tumor cells are resistant to apoptosis and express FasL. The T cell recognizes tumor cells but undergoes apoptosis by Fas–FasL interaction (tumor counterattack).
Fas ligand expression in the thyroid

Fas ligand expression has been reported to occur only in activated cytotoxic T lymphocytes and natural killer cells and tissues such as the eye and testis, which are regarded as ‘immune privileged’ (17, 28). Cells from these tissues are protected from cytotoxic T cells by FasL expression which binds to Fas antigen on lymphocytes and induces apoptosis. Recently, FasL expression was also detected in some tumor cells including those of epithelial origin (27). By expressing FasL, these cells are able to induce apoptosis in Fas-positive cells of the immune system, escaping immune surveillance. FasL expression on thyrocytes is controversial. Giordano et al. (29) reported constitutive FasL expression on thyroid cells from both non-toxic goiter and HT tissues. Fas and FasL expression on thyrocytes suggests that cell death may be spontaneously induced in neighboring thyroid cells (Fig. 3). Indeed, cultured normal thyrocytes expressed Fas antigen after treatment with interleukin 1β (IL-1β) and underwent apoptosis by Fas–FasL interaction (29). However, massive apoptosis has not been reported in vivo. In contrast, apoptosis and destruction of thyroid cells appear to occur more gradually (22–24), questioning the relevance of this theory (30).

The report by Giordano et al. (29) was further criticized because it employed antibodies that appeared to recognize a protein that was not FasL (31). Furthermore, other groups examined the expression of FasL on thyrocytes using different techniques and failed to show the expression of mRNA for FasL in thyrocytes from normal, HT and GD thyroid tissues (32, 33). A more recent study (34) employing monoclonal antibodies against human FasL reported that FasL expression was only observed in GD thyroid tissues and not in normal thyroids. Other investigators have examined the expression of FasL in thyroid carcinomas

![Figure 3](https://www.eje.org)

**Figure 3** A model for thyroid cell destruction. Neighboring thyroid cells possibly destroy each other by expressing Fas and FasL. The soluble form of FasL (sFas), resulting from cleavage of FasL by a metalloproteinase (MP), can induce apoptosis in the same or adjacent cells (autocrine suicide or paracrine fratricide).
from cleavage at the cell membrane by a metallo-
B cells respectively from apoptosis. antibody by protecting thyroid cells and autoreactive proliferation and production of anti-TSH receptor splicing) and reduced Fas expression on cell surface. of a Fas mRNA variant (which results from alternative increased number of these cells. Although the induc-
thyroid cells and infiltrating lymphocytes, or the result from either the increased production of sFas in thyrotoxic patients with GD. The levels of sFas were reduced when patients became euthyroid after treatment with antithyroid drugs for 6–8 weeks. The serum levels of sFas have recently been measured in patients with autoimmune thyroid diseases (38). In contrast to normal controls, sFas was increased in thyrotoxic patients with GD, but reduced in patients with GD in remission. Additionally, sFas was normal in hypothyroid patients with HT and thyrotoxic patients with silent thyroiditis. The above data were later confirmed by others (39), who also measured high levels of sFas in thyrotoxic patients with GD. The levels of sFas were reduced when patients became euthyroid after treatment with antithyroid drugs for 6–8 weeks. It is not yet clear if the elevated serum levels of sFas result from either the increased production of sFas in thyroid cells and infiltrating lymphocytes, or the increased number of these cells. Although the induction of sFas production by inflammatory cytokines seems to support the former theory, the latter is also possible as thyroid hyperplasia is a characteristic of GD.

Increased sFas in GD indicates increased expression of a Fas mRNA variant (which results from alternative splicing) and reduced Fas expression on cell surface. The increased sFas is likely to promote thyrocyte proliferation and production of anti-TSH receptor antibody by protecting thyroid cells and autoreactive B cells respectively from apoptosis.

FasL is also detected in a soluble form (sFasL) resulting from cleavage at the cell membrane by a metallo-

### Soluble form of Fas and FasL and apoptosis of thyroid cells

Recently, Cheng et al. (36) described an alternatively spliced Fas mRNA that results from deletion of exons 3, 4, 6 and 7. This mRNA encodes the soluble form of Fas (sFas) lacking the transmembrane domain of this receptor. sFas is supposed to inhibit Fas–FasL interaction and protect target cells from Fas-induced apoptosis. Serum levels of sFas were reported to be elevated in patients with systemic lupus erythematosus or rheumatoid arthritis (37). Some studies showed a significant correlation between sFas levels and the clinical and laboratory findings of these diseases, although other groups were not able to confirm this suggestion.

The presence of Fas alone, however, may not be enough to induce apoptosis in cells. Recent evidence suggests that regulation of Fas-induced apoptosis in thyroid cells may be more complex than previously thought. Indeed, studies by Arscott et al. (41) suggest that the Fas pathway is blocked at some point by a short-lived (labile) inhibitor. It was reported that the induction of apoptosis on thyrocytes using anti-Fas monoclonal antibody requires the presence of cyclo-

Fas-mediated apoptosis in thyroid disease

Regulation of the Fas pathway in the thyroid gland

In immunohistochemical studies of thyroid tissue sections found Fas protein present on thyroid follicular cells from healthy individuals, as well as from patients with thyroid carcinomas, GD and HT, although the extent and specific disorders associated with this expression differed between the studies (22, 23). In thyrocyte cultures, Fas protein was detected either by antibodies against Fas antigen (24, 41, 42), or by Western blots in cell lysates (41). However, it was recently reported that Fas expression is induced on thyrocytes only under the influence of inflammatory cytokines, such as interferon-γ (IFN-γ) or IL-1β (29). The differences between the studies may result from differences in reagents or tissues examined.

The presence of Fas alone, however, may not be enough to induce apoptosis in cells. Recent evidence suggests that regulation of Fas-induced apoptosis in thyroid cells may be more complex than previously thought. Indeed, studies by Arscott et al. (41) suggest that the Fas pathway is blocked at some point by a short-lived (labile) inhibitor. It was reported that the induction of apoptosis on thyrocytes using anti-Fas monoclonal antibody requires the presence of cyclo-

www.eje.org
Role of Fas pathway in the pathogenesis of thyroid diseases

Hashimoto’s thyroiditis

HT is characterized by an immune response to thyroid antigens and an intense lymphocytic infiltration of the thyroid gland, resulting in the destruction of thyroid follicular cells and clinical hypothyroidism (47). HT is associated with thyroid-specific B cells as well as with T cell immune responses. There are antibodies to thyroid peroxidase and thyroglobulin, while the majority of intrathyroidal T cells are CD8 phenotype indicating cytotoxic activity against thyrocytes (48, 49). The above evidence is the reason why, until now, most of the investigations into the pathogenesis of autoimmune thyroid disease have focused on the immune system.

Extensive research in this field demonstrated that even the development of an antithyroid immune response does not necessarily lead to thyroid cell destruction and clinical hypothyroidism. This is the reason why other factors have been examined for their contribution to the pathogenesis of autoimmune thyroid disease (30). As mentioned above, thyroid follicular cells in tissue samples from HT exhibited strong staining for Fas and FasL, and high apoptotic rate (30.3%), while normal control follicles exhibited moderate Fas, minimal or no FasL and a low percentage of apoptosis (24). Immunostaining for Bcl-2 was weak in patients’ thyroid follicles and high in normal controls. Infiltrating lymphocytes exhibited weak staining for FasL and strong for Bcl-2 (24, 46). These data suggest that, in HT, thyroid follicular cells undergo apoptosis by up-regulation of Fas and FasL and down-regulation of Bcl-2 protein. Infiltrating lymphocytes do not seem to be directly involved in this process with their own FasL, but they are likely to provide the appropriate cytokine milieu that results in the up-regulation of Fas and FasL, and subsequently the activation of the apoptotic machinery.

Graves’ disease

GD is considered to be an autoimmune thyroid disorder. It is characterized by hyperplasia of thyrocytes resulting from stimulation with anti-TSH receptor autoantibodies. Although thyrocytes from GD patients express both Fas and FasL in vivo, apoptosis was only occasionally found in the GD thyroids (34). The expression of FasL in GD thyrocytes, the down-regulation of Fas expression by the stimulation of TSH receptor and the over expression of Bcl-2 (an inhibitor of apoptosis) or the presence of a labile protein inhibitor (41) have been proposed as possible factors for the inhibition of Fas-mediated apoptosis in Graves’ thyrocytes.

Other studies have addressed the role of sFas, which suppresses Fas-mediated apoptosis in the pathogenesis of GD. They confirmed that serum sFas increases in GD and provided evidence of local production of sFas by thyrocytes and its regulation by cytokines. These studies suggest that sFas, by interfering with the Fas–FasL interaction, may also play a role in the pathogenesis of GD (38, 39).

Apoptosis induced by Fas may also be involved in the peripheral deletion of B cells activated by self antigens. The increased sFas may block this process and B cells escaping that deletion may be responsible for the production of TSH receptor antibody in GD (38). Apparently, the soluble form of Fas seems to be involved in the pathogenesis of GD, but further studies are needed to determine either the pathogenic or the protective role of sFas in this disease.

The increased expression of FasL in thyrocytes from GD patients may help to maintain homeostasis in the thyroid by eliminating infiltrating lymphocytes and hyperplastic thyrocytes by Fas-mediated apoptosis (34). Further studies are required to elucidate the mechanisms responsible for the FasL expression in the thyroid in GD.

Thyroid carcinomas

Apoptosis may play an important role in cancer. Many tumors have been found to be not only resistant to killing by apoptosis, but also to express functional FasL constitutively. This suggests that they may carry ‘weapons’, like the death ligands, to fight the immune system. The result of this ‘tumor counterattack’ may be the depletion of the attacking anti-tumor lymphocytes by the tumor, immunosuppression and immune escape. The ability of the neoplastic cell to escape the host’s immune surveillance and to kill infiltrating immune cells is a strong survival advantage during the course of cancer progression (35).

In contrast to normal thyroid tissue, papillary carcinomas showed FasL immunoreactivity, especially in areas of poor and/or squamous differentiation. In a co-culture experiment, thyroid carcinoma cells were found to induce FasL-dependent apoptosis in Fas-sensitive cells of lymphocytic origin, suggesting that FasL in thyroid carcinomas is functional. From the laboratory findings, it appears that FasL expression is limited to papillary, follicular and Hurthle carcinomas, while FasL immunoreactivity in medullary carcinomas was poor or absent (35).

Consequently, it has been suggested that FasL expression helps thyroid carcinoma cells to evade the immune system by inducing apoptosis of infiltrating lymphocytes. This raises the question of why FasL-expressing tumor cells do not undergo apoptotic
suicide/fratricide as they express Fas receptor. Previous studies showed a low rate of apoptotic cells in thyroid carcinomas. It appears that FasL expressed on the neoplastic thyrocyte is directed against cells of the immune system and not the thyrocyte itself, probably due to a defect in the tumor cell apoptotic pathway, or the presence of a protein inhibitor of apoptosis that protects the cell from suicide.

Goiter

Under normal conditions, the size of the thyroid gland during adulthood remains relatively constant because cell proliferation is balanced by cell death. This balance may be disturbed in human goiter, which is the result of diffuse or focal hyperplasia of thyroid follicular cells at one or multiple sites within the thyroid gland.

The role of apoptosis and the involvement of the Fas pathway were previously investigated in rat models of goiter during the stages of goiter formation and involution (50). Rats were fed a low iodine diet and a goitrogem, 6-propyl-2-thiouracil. Later, the same rats with goiter were fed a high iodine diet to study the phase of involution. The major findings of this study were an increased number of apoptotic cells paralleled by an increased number of Fas-positive cells during the development of goiter and the early stage of involution but a decreased number of Fas-positive cells in the late stage of goiter involution. Constitutive expression of Fasl was observed throughout the experiment. These findings suggest that Fas expression may serve as a limiting factor for the induction of Fas-mediated apoptosis.

We have studied the expression of Fas in vivo in thyrocytes from patients with non-toxic nodular goiter who underwent fine needle aspiration biopsy for diagnostic reasons (authors’ unpublished observations). The results showed that the expression of Fas protein is low in human nodular goiter, indicating reduced thyroid cell apoptosis through the Fas pathway. Therefore, the regulation of Fas protein expression may play a role in the pathogenesis of goiter by upsetting the normal balance between thyroid cell proliferation and apoptosis in favor of the former process.

Besides the Fas/FasL system, iodine may also be involved in the death of thyrocytes and the control of thyroid gland mass. High doses of iodine inhibit the proliferation of FRTL-5 cells and induce cell toxicity both in vivo and in vitro, possibly due to an excessive production of free radicals. The role of iodine in inducing apoptosis was also investigated in thyroid cell cultures. Low concentrations of iodine were capable of inhibiting apoptosis, while high concentrations resulted in increased Fas-induced apoptosis (51).

The above findings indicate that the delicate balance between thyroid cell proliferation and apoptosis may play a central role in the control of thyroid gland mass. Further studies are needed to clarify the role of apoptosis and the Fas pathway in the pathogenesis of goiter.

Conclusion

Fas-mediated apoptosis may play an important role in thyroid tissue homeostasis as well as in thyroid disease, since morphological and biochemical features of programmed cell death have been observed in normal thyroid glands and in various thyroid diseases. However, the mechanisms and regulation of apoptosis in thyrocytes remain unclear. Further studies are required to clarify the signaling components of programmed cell death present in thyroid cells and the in vivo regulatory mechanisms of this process. The regulation of apoptotic cell death pathways in the thyroid may alter the expression of thyroid diseases by modifying the susceptibility of thyroid cells to Fas-mediated apoptosis and may offer new therapeutic options.

References

2. Esposti MD. Apoptosis: who was first? Cell Death and Differentiation 1998 5 719.

www.eje.org
M Andrikoula and A Tsatsoulis

17 Griffith TS, Brunner T, Fletcher SM, Green DR & Ferguson TA. 

18 Weetman AP & McGregor AM. Autoimmune thyroid disease. 
Endocrine Reviews 1984 5 309–337.

19 Winqvist O, Soderbergh A & Kampe O. The autoimmune basis of 
adrenocortical destruction in Addison’s disease. Molecular 

20 Fouli A. The pathology of the endocrine pancreas in type 

21 Chervonsky AV, Wang Y, Wong F, Visintin I, Flavell RA, 
Janeway CA Jr et al. The role of Fas in autoimmune diabetes. 

22 Tanimoto C, Hirakawa S, Kawasaki H, Hayakawa N & Ota Z. 
Apoptosis in thyroid tissues of patients with Hashimoto’s thyroiditis. Autoimmunity 1995 20 231–236.

23 Kotani T, Aratake Y, Hirai K, Fukazawa Y, Sato H & Ohtaki S. 

24 Hammond LJ, Lowbell MW, Ceranno PG, Goode AW, Bottazzo GF & 
Mirakian R. Analysis of apoptosis in relation to tissue 

25 Ridgway WM, Weiner HL & Fathman CG. Regulation of 

26 Lowin B, Hahne M, Mattmann C & Tschopp J. Cytolytic T-cell 
cytotoxicity is mediated through perforin and Fas lytic pathways. 

27 Hahne M, Rimoldi D & Schroter M. Melanoma cell expression of 
Fas (Ap0-1/CD95) ligand: implications for tumor immune 


29 Giordano C, Stassi G, DeMaria R, Todaro M, Richiusa P, Papoff G 
et al. Potential involvement of Fas and its ligand in the 

Immunology and Immunopathology 1998 87 207–217.

31 Fiedler P, Schaetzlein CE & Eibl H. Constitutive expression of 

32 Rymasaewski M, Arscott PL, Knapp J, Brezt JD, Thompson ND, 
Bartron J et al. Constitutive expression of Fasl ligand on 

33 Stokes TA, Rymasaewski M, Arscott PL, Wang SJ, Brezt JD, 
Bartron J et al. Constitutive expression of Fasl in thyrocytes 

34 Hiromatsu Y, Hoshino T, Yagitza H, Koga M, Sakisaka S, Honda J 
et al. Functional Fas ligand expression in thyrocytes from patients 
with Graves’ disease. Journal of Clinical Endocrinology and 
Metabolism 1999 84 2896–2902.

35 Mitsiades N, Poulaki V, Mastorakos G, Tseleni-Balafouta S, 
Kotoula V & Koutras DA. Fas ligand expression in thyroid 
carcinomas: a potential mechanism of immune evasion. 

Protection from Fas-mediated apoptosis by a soluble form of the 

37 Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y 
et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular 
structure in systemic Lupus erythematosus (SLE) and other 
autoimmune diseases. Clinical and Experimental Immunology 
1997 107 89–95.

38 Shimaoka Y, Hidaka Y, Okumura M, Takeoka K, Tada H & 
Amino N. Serum concentration of soluble Fas in patients with 
autoimmune thyroid diseases. Thyroid 1998 8 43–47.

39 Hiromatsu Y, Bednarzak T, Soyejima E, Miyake I, Yang D, 
Fukazawa H et al. Increased serum soluble Fas in patients with 

40 Tanaka M, Suda T, Takahashi T & Nagata S. Expression of the 
fractional soluble form of human Fas ligand in activated 

41 Arscott PL, Knapp J, Rymasaewski M, Bartron JL, Brezt JD & 
Thompson ND. Fas/APO-1, CD95-mediated apoptosis in thyroid 

42 Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Kawabe Y, 
Ishikawa N et al. Thyroid-stimulating hormone inhibits Fas 
antigen-mediated apoptosis of human thyrocytes in vitro. 
Endocrinology 1997 137 3163–3169.

43 Yanagisawa J, Takahashi M, Kanki H, Yano-Yanagisawa H, 
Tazunoki T, Sawa E et al. The molecular interaction of Fas and 
FAP-1: a tripeptide blocker of human Fas interaction with FAP-1 
promotes Fas-induced apoptosis. Journal of Biological Chemistry 
1997 272 8539–8545.

44 Hu S, Vincenz C, Ni J, Gentz R & Dixit VM. I-F LiCE, a novel 
hitributor of tumor necrosis factor receptor-1 and CD95- 
duced apoptosis. Journal of Biological Chemistry 1997 272 
17255–17257.

45 Chiu UK, Walsh CM, Liu CC, Reed JC & Clark WR. Bcl-2 blocks 
degranulation but not Fas-based cell mediated cytotoxicity. 

46 Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-Balafouta 
ST, Koutras DA et al. Fas/Fas ligand up-regulation and 
Bcl-2 down-regulation may be significant in the patho- 
genesis of Hashimoto’s thyroiditis. Journal of Clinical Endocrinology 
and Metabolism 1998 83 2199–2203.

47 Weetman AP & McGregor AM. Autoimmune thyroid disease: 
 further developments in our understanding. Endocrine Reviews 

48 Bermann M, Magee M & Koenig RJ. Differential autoantibody 
responses to thyroid peroxidase in patients with Grave’s disease 
and Hashimoto thyroiditis. Journal of Clinical Endocrinology 
and Metabolism 1997 82 998–1011.

49 DeGroot LJ & Quintans J. The causes of autoimmune thyroid 

50 Tamura M, Kimura H, Koji T, Tominaga T, Ashizawa K, 
Kotoula V & Koutras DA. Fas/APO-1 and 
Thyroid-stimulating hormone inhibits Fas/APO-1 and 
Thyroid-stimulating hormone inhibits Fas/APO-1. Endocrinology 
1999 139 3646–3653.

51 Feil Thieme P, Eberhart A & Scherbaum VA. Fas-mediated 
apoptosis is inhibited by TSH and iodide in moderate 
conzentra- tions in primary human thyrocytes in vitro. Hormone and 

Received 4 August 2000 
Accepted 16 February 2001